for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

64.29USD

Change

-0.78(-1.20%)

Volume

6,163,634

Today's Range

63.72

 - 

65.17

52 Week Range

60.32

 - 

72.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
65.07
Open
64.88
Volume
6,163,634
3M AVG Volume
127.29
Today's High
65.17
Today's Low
63.72
52 Week High
72.90
52 Week Low
60.32
Shares Out (MIL)
1,265.15
Market Cap (MIL)
82,323.02
Forward P/E
9.27
Dividend (Yield %)
3.87

Next Event

Dividend For GILD.OQ - 0.6300 USD

Latest Developments

More

Sierra Oncology And Gilead Sciences Agree On Amendments To Asset Purchase Agreement For Momelotinib

U.S. HHS Says United States Filed Patent Infringement Lawsuit Against Gilead Related To Truvada And Descovy For Pre-Exposure Prophylaxis Of HIV

Gilead's Biktarvy Maintained High Efficacy Through 3 Years In Late-Stage HIV Trials

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry

Biotechnology & Drugs

Contact Info

333 LAKESIDE DR

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Andrew Dickinson

Chief Financial Officer

Brett Alan Pletcher

Executive Vice President, Chief Compliance Officer, General Counsel

Jyoti Mehra

Executive Vice President of Human Resources

Johanna Mercier

Chief Commercial Officer

Key Stats

2.14 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

30.4K

2017

26.1K

2018

22.1K

2019(E)

22.3K
EPS (USD)

2016

11.570

2017

8.840

2018

6.670

2019(E)

7.023
Price To Earnings (TTM)
30.91
Price To Sales (TTM)
3.68
Price To Book (MRQ)
4.00
Price To Cash Flow (TTM)
20.06
Total Debt To Equity (MRQ)
119.34
LT Debt To Equity (MRQ)
107.21
Return on Investment (TTM)
5.20
Return on Equity (TTM)
4.36

Latest News

Latest News

Merck loses bid to revive $2.54 billion patent verdict against Gilead

A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc <MRK.N> as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc <GILD.O>.

Merck loses bid to revive $2.54 billion patent verdict against Gilead

A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc.

Gilead third-quarter results in line, but Yescarta sales dip

Gilead Sciences Inc <GILD.O> on Thursday posted third-quarter results largely in line with Wall Street estimates, led by higher HIV drug sales, but sales of cancer cell therapy Yescarta fell slightly from the previous quarter.

Gilead posts third-quarter net loss, sales in line with Street estimates

Gilead Sciences Inc on Thursday reported third-quarter results largely in line with Wall Street estimates, led by higher sales of its HIV drugs, but deal-related costs led to a net loss.

BRIEF-Gilead Sciences Appoints Merdad Parsey As Chief Medical Officer

* GILEAD SCIENCES APPOINTS MERDAD PARSEY, MD, PHD AS CHIEF MEDICAL OFFICER

U.S. FDA approves Gilead's Descovy for HIV prevention

The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's <GILD.O> Descovy to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

U.S. FDA approves Gilead's HIV prevention treatment

The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's drug, Descovy, to reduce the risk of sexually acquired HIV infection.

FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

GSK's long acting HIV injection gets boost from study

GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences.GSK's two-drug injection was as effective...

Medicare to cover expensive cancer cell therapies

The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc <GILD.O> and Novartis AG <NOVN.S>.

Patient groups push back against Gilead's pricey HIV prevention treatment

Gilead Sciences Inc <GILD.O> hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates.

FDA panel backs Gilead's HIV prevention drug Descovy, except in women

An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

FDA panel backs Gilead's HIV prevention drug for certain population

Independent experts on an FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc <GILD.O> and Novartis AG <NOVN.S>, new data shows, helping explain why sales of the two products have not met rosy expectations.

Gilead results beat Street estimates as demand grows for HIV drug

Gilead Sciences Inc <GILD.O> beat Wall Street estimates for second-quarter revenue and profit on Tuesday, driven by higher sales of HIV treatments, and the U.S. drugmaker raised its full-year sales forecast.

Gilead quarterly profit rises 3.5%

Gilead Sciences Inc reported a 3.5% rise in quarterly profit on Tuesday, as higher sales of its HIV drugs cushioned sluggish demand for its flagship hepatitis C treatments.

BRIEF-Gilead Sciences Licenses Respiratory, Herpes Antiviral Research Programs From Novartis

* GILEAD SCIENCES LICENSES RESPIRATORY AND HERPES ANTIVIRAL RESEARCH PROGRAMS FROM NOVARTIS

GSK's two-drug HIV Dovato treatment meets main goal in study

(This July 10 story corrects to show patients switched from Gilead's Descovy, not Gilead's Vemlidy, in fifth paragraph)

CORRECTED-UPDATE 1-GSK's Dovato suppresses AIDS virus at same levels of 3-drug regimen (July 10)

GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up